T-cell receptor beta variable 19 (TCR Vβ17) (TRBV19)

T-cell receptor beta variable 19 (commonly known as TCR Vβ17) is a specific variable segment of the T-cell receptor beta chain that plays a critical role in the adaptive immune system by mediating antigen recognition. In several autoimmune conditions, such as Multiple Sclerosis and Rheumatoid Arthritis, specific T-cell clones expressing the Vβ17 segment undergo pathological expansion and target self-antigens, such as myelin basic protein, leading to tissue damage [1][2]. Because these pathogenic T cells often exhibit restricted TCR Vβ usage, they represent a highly specific therapeutic target for selective immunotherapy. Therapeutic strategies targeting these cells often involve TCR-specific vaccines, such as NeuroVax, which are designed to induce an anti-idiotypic immune response where the patient's own immune system generates regulatory T cells to suppress the Vβ17-expressing autoreactive clones [3][4]. This approach aims to restore immune tolerance and reduce disease activity without causing the global immunosuppression associated with traditional treatments [5]. Monitoring the prevalence and clonal expansion of Vβ17-expressing cells in clinical samples serves as both a diagnostic tool and a biomarker for treatment efficacy.

Other names

T-cell receptor variable beta 17Vβ17TRBV19TCRBV17S1Autoreactive T cells expressing TCR Vβ17

Induction of anti-idiotypic immune responses to selectively deplete or suppress autoreactive T-cell clones expressing the specific Vβ17 TCR chain.